We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Siemens and Janssen Collaborate on Companion Diagnostic

By LabMedica International staff writers
Posted on 24 Jun 2013
Siemens Healthcare Diagnostics (Tarrytown, NY, USA) has entered into a collaboration with Janssen Pharmaceutica NV (Beerse, Belgium) to design, develop, and commercialize a companion diagnostic test associated with an early-stage compound being developed by Janssen. More...
The compound targets autoantibodies directed against the human β1-adrenergic receptor (β1-AR) that could contribute to the development of heart failure.

Under the agreement, the Siemens Clinical Laboratory (SCL) will work with Janssen to design immunoassay-based companion diagnostic tests for use in Janssen's clinical studies. Siemens will develop and validate an in vitro diagnostic test as a companion diagnostic for the Janssen therapeutic product. The Siemens Clinical Laboratory (SCL) is a high-complexity testing laboratory designed to advance personalized medicine.

Heart failure is generally a progressive disease characterized by the heart muscle’s inability to adequately pump oxygenated blood through the body. For most causes of heart failure, there is no known cure.

“Our relationship with Janssen marks an important next step in Siemens’ personalized medicine strategy,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. “As a leading clinical diagnostics company, with the tools and technologies to help define the future of patient care, we are looking forward to collaborating with Janssen and extending their position in cardiac therapies.”

Related Links:

Siemens Healthcare Diagnostics
Janssen Pharmaceutica NV



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
Clinical Informatics Platform
CLARION™
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.